相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DPP-4 inhibitors and angioedema: a cause for concern?
Jennifer S. Byrd et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2011)
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Wendy L. Bennett et al.
ANNALS OF INTERNAL MEDICINE (2011)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
David W. Boulton et al.
CLINICAL PHARMACOKINETICS (2011)
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
Deanna S. Kania et al.
CLINICAL THERAPEUTICS (2011)
Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
R. Keith Campbell
CLINICAL THERAPEUTICS (2011)
Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
Masanori Abe et al.
CURRENT DRUG METABOLISM (2011)
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Nir Barzilai et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors
Tetsuhiro Tanaka et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2011)
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
Pleun C. M. van Poppel et al.
DIABETES CARE (2011)
Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
Marjolein J. Willemen et al.
DIABETES CARE (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population >= 75 years: a pooled analysis from a database of clinical trials
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
A. J. Tremblay et al.
DIABETES OBESITY & METABOLISM (2011)
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin
B. Ahren et al.
DIABETES OBESITY & METABOLISM (2011)
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin
U. Graefe-Mody et al.
DIABETES OBESITY & METABOLISM (2011)
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
K. Esposito et al.
DIABETES OBESITY & METABOLISM (2011)
Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes
R. R. Henry et al.
DIABETES OBESITY & METABOLISM (2011)
Regulation of glucagon secretion by incretins
J. J. Holst et al.
DIABETES OBESITY & METABOLISM (2011)
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
P. Anagnostis et al.
DIABETES OBESITY & METABOLISM (2011)
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
M. Nowicki et al.
DIABETES OBESITY & METABOLISM (2011)
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
V. Lukashevich et al.
DIABETES OBESITY & METABOLISM (2011)
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
B. Ahren et al.
DIABETES OBESITY & METABOLISM (2011)
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide
Thomas L. Seck et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials
Matteo Monami et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2011)
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
D. R. Owens et al.
DIABETIC MEDICINE (2011)
Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial
J. E. Foley et al.
DIABETOLOGIA (2011)
Linagliptin In Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2011)
Sitagliptin/Metformin Fixed-Dose Cambination In Patients with Type 2 Diabetes Mellitus
Claudine M. Chwieduk
DRUGS (2011)
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences
Roberta Baetta et al.
DRUGS (2011)
Sitagliptin reduces albuminuria in patients with type 2 diabetes
Sachiko Hattori
ENDOCRINE JOURNAL (2011)
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Cytochrome P450-mediated cardiovascular drug interactions
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy
Baptist Gallwitz
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
M. Nowicki et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Isoglycemic Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
Irfan Vardarli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Type 2 Diabetes Mellitus and Renal Impairment in a Large Outpatient Electronic Medical Records Database: Rates of Diagnosis and Antihyperglycemic Medication Dose Adjustment
Juliana L. Meyers et al.
POSTGRADUATE MEDICINE (2011)
Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
Susumu Ogawa et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
Zubair Shah et al.
VASCULAR PHARMACOLOGY (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
Anja Schweizer et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2011)
Treatment of Elderly Patients With Type 2 Diabetes Mellitus: A Systematic Review of the Benefits and Risks of Dipeptidyl Peptidase-4 Inhibitors
Sherwyn L. Schwartz
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY (2010)
Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
Joshua J. Neumiller et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
Sitagliptin-Associated Drug Allergy: Review of Spontaneous Adverse Event Reports
Shrey Desai et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2010)
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
Mark Kirby et al.
CLINICAL SCIENCE (2010)
The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes Possible role of stromal-derived factor-1α
Gian Paolo Fadini et al.
DIABETES CARE (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
D. R. Matthews et al.
DIABETES OBESITY & METABOLISM (2010)
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin
R. Retnakaran et al.
DIABETES OBESITY & METABOLISM (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
DPP-4 inhibitors: What may be the clinical differentiators?
John Gerich
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study
M. A. Banerji et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach
Paolo Pozzilli et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
Andre J. Scheen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
R. A. DeFronzo et al.
DIABETIC MEDICINE (2010)
Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
P. C. Butler et al.
DIABETOLOGIA (2010)
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
G. Schernthaner et al.
DIABETOLOGIA (2010)
Alogliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2010)
Sitagliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Sohita Dhillon
DRUGS (2010)
Vildagliptin A Review of its Use in Type 2 Diabetes Mellitus
Gillian M. Keating
DRUGS (2010)
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
Annis Marney et al.
HYPERTENSION (2010)
Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome
Edwin K. Jackson
HYPERTENSION (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
S. S. Engel et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
Olivia J. Phung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Addition of incretin therapy to metformin in type 2 diabetes
Andre J. Scheen et al.
LANCET (2010)
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
Giuseppe Derosa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
M. Monami et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
Walid K. H. Fakhoury et al.
PHARMACOLOGY (2010)
Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
PHARMACOTHERAPY (2010)
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Robert Frederich et al.
POSTGRADUATE MEDICINE (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Drug evaluation: Vildagliptin-metformin single-tablet combination
Abd A. Tahrani et al.
ADVANCES IN THERAPY (2009)
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
ADVANCES IN THERAPY (2009)
Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes
Rajesh Gupta et al.
CURRENT DRUG TARGETS (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone
R. Chapell et al.
DIABETES OBESITY & METABOLISM (2009)
Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)
A. J. Scheen et al.
DIABETIC MEDICINE (2009)
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
D. M. Nathan et al.
DIABETOLOGIA (2009)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
Manfredi Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Vildagliptin in clinical practice: a review of literature
Moulinarh Banerjee et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Nancy J. Brown et al.
HYPERTENSION (2009)
Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
Michael Boschmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Joshua J. Neumiller
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Barbara J. Zarowitz et al.
PHARMACOTHERAPY (2009)
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2008)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
New Drugs for Type 2 Diabetes Mellitus What is their Place in Therapy?
Andrew J. Krentz et al.
DRUGS (2008)
Incretin-based therapies in type 2 diabetes mellitus
Chee W. Chia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Exenatide once weekly in type 2 diabetes
Andre J. Scheen
LANCET (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim et al.
PHARMACOLOGICAL REVIEWS (2008)
Novel combination treatment of type 2 diabetes DPP-4 inhibition
Bo Ahren
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
Nasser Mikhail
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight
E. Bonora
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
Arthur J. Bergman et al.
DIABETES CARE (2007)
A review of the effects of anti hyperglycaemic agents on body weight: the potential of incretin targeted therapies
Anthony Barnett et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin
Y.-L. He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes
Adrian Vella et al.
DIABETES (2007)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Current management strategies for coexisting diabetes mellitus and obesity
AJ Scheen
DRUGS (2003)
分享论文
